New EMEA NSAID Study Could Put Teeth In EU Labeling Suggestion
This article was originally published in The Tan Sheet
The European Medicines Agency is considering whether it should pursue mandatory NSAID labeling requirements across the European Union that would warn of increased risk of thrombotic events associated with use of products in the category
You may also be interested in...
Traditional non-selective NSAIDs, with the exception of naproxen, carry similar cardiovascular risk to COX-2 inhibitors, according to results of a study released by the Agency for Healthcare Research & Quality (AHRQ) Sept. 25
Labeling regarding established NSAID safety concerns should be made consistent across European Union member states, the European Medicines Agency said Oct. 17
“To the extent these claims pertain to the ingestion of peanuts, they are not consistent with the claim in the  Letter of Enforcement Discretion FDA issued in response to a petition for a qualified health claim for ground peanuts and reduced risk of developing peanut allergy,” state CFSAN officials.